Open Peer Review on Qeios

Neoantigen-based Glioblastoma Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Neoantigen-based Glioblastoma Vaccine</u>. NCI Thesaurus. Code C118960.

A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based glioblastoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CT L) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens are tumor-specific antigens derived from mutated proteins that are present only in a specific tumor.